Clinical phase Alzheimer’s disease drugs 2024, by sponsor

Published by
Matej Mikulic,
May 3, 2024
As of January 1, 2024, nearly 80 percent of all Alzheimer’s disease drugs in clinical trial phases 1, 2, and 3 combined worldwide were sponsored by the biopharma industry. This statistic illustrates the trial sponsors of Alzheimer’s disease drugs in development worldwide, by sponsor.

Share of Alzheimer’s disease drugs in clinical trials worldwide as of 2024, by sponsor

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

April 2024

Region

Worldwide

Survey time period

as of January 1, 2024

Supplementary notes

The statistic describes the distribution of 164 active phase 1, 2, and 3 trials, as of January 1, 2024.
* Includes academic medical centers/NIH and public-private partnerships (PPP).

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Dementia and Alzheimer's disease in Europe "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Dementia and Alzheimer's disease in Europe

World overview

6

European focus

5

Mortality and morbidity

8

Situation in specific countries

8

Policies directed towards dementia

8

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Clinical trialsGlobal pharmaceutical industryPharmaceutical industry in the U.S.Top pharmaceutical drugsCoronavirus (COVID-19) vaccines and treatments
All features, all contents, at all times: Learn more about our professional solutions.

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.